Quarterly Result1 Aug 2026, 05:20 pm
Aarti Drugs Q1 FY27 Revenue Up 19% YoY to ₹703.6 Cr
AI Summary
Aarti Drugs Limited reported its unaudited financial results for the quarter ended June 30, 2026. Total revenue increased by 19% year-on-year to ₹703.6 crore from ₹590.8 crore in Q1 FY26. EBITDA grew by 30% YoY to ₹96.9 crore, with EBITDA margin expanding by 120 basis points to 13.8%. Profit Before Tax (PBT) rose 35% YoY to ₹69.2 crore. However, Profit After Tax (PAT) saw a 7% decline to ₹50.1 crore, impacted by a principal tax refund of approximately ₹15 crores in Q1 FY26. The company highlighted strong performance in Specialty Chemicals, with revenue up 150% YoY. Management cited volume growth, improved realizations, operational efficiencies, and product mix optimization as key drivers.
Key Highlights
- Total revenue grew 19% YoY to ₹703.6 crore.
- EBITDA increased 30% YoY to ₹96.9 crore, with margins expanding.
- Specialty Chemicals segment revenue surged 150% YoY.
- PAT declined 7% YoY due to a prior year tax refund.
- Company expanding oral solid dosage capabilities in Baddi.
Price Impact
More from AARTIDRUGS